Compass Pathways plc Depositary Receipt (CMPS)
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical Officer Steve Levin - Chief Patient Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Athena Chin - TD Cowen Sumant Kulkarni - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Lori Englebert - Chief Commercial Officer Teri Loxam - Chief Financial Officer Michael Gold - Chief Research & Development Officer Guy Goodwin - Chief Medical Officer Steve Levine - Chief Patient Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Paul Matteis - Stifel Ritu Baral - TD Cowen Charles Duncan - Cantor Leonid Timashev - RBC Capital Markets Patrick Trucchio - H.C. Wainwright & Co. François Brisebois – Oppenheimer Sumant Kulkarni - Canaccord Genuity Michael Rabinowitz - Maxim Group Vikram Purohit - Morgan Stanley Operator Ladies and gentleman thank you for standing by, and welcome to the COMPASS Pathways' Ltd.
COMPASS Pathways plc (CMPS) Q3 2024 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Lori Englebert - Chief Commercial Officer Teri Loxam - Chief Financial Officer Michael Gold - Chief Research & Development Officer Guy Goodwin - Chief Medical Officer Conference Call Participants Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor François Brisebois - Oppenheimer Elemer Piros - Rodman Patrick Trucchio - H.C. Wainwright & Co. Tom Shrader - BTIG Sumant Kulkarni - Canaccord Genuity Operator Thank you for standing by.
Psychedelic Stocks: Focus On Their Cash
Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks.
COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript
COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxam - CFO Conference Call Participants Ritu Baral - TD Cowen Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor Vikram Purohit - Morgan Stanley Gavin Clark-Gartner - Evercore ISI Sumant Kulkarni - Canaccord Genuity Tom Shrader - BTIG Elemer Piros - Rodman Operator Good day, ladies and gentlemen, and welcome to COMPASS Pathways' Second Quarter 2024 Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN. The company addresses unmet mental health needs through psychedelic therapies. COMP360 showed promising results in Phase 2 trials for PTSD, with significant improvements in depression symptoms.
